Abstract 93P
Background
Endometrial carcinomas (EC) are the most common gynecological cancer in the developed world. The original histopathology-based classification has been supplemented in the recent years by a molecular classification, based on the analysis of POLE mutation, microsatellite instability (MSI) and copy number variation. These markers have been used to develop prognostic risk groups with specific treatment options. Hence, the molecular stratification has been recommended internationally by different organizations and associations (e.g., ESMO, ESGO), allowing individualized treatment stratifications. Historically, these markers have been analyzed by various methods such as immunohistochemistry (IHC), Sanger sequencing and PCR-based fragment analysis. But the lack of single streamlined workflow has hampered the widespread adoption.
Methods
We developed three assays for discrimination of EC into ultramutated (POLE), hypermutated (MSI) and copy number high (CN high) phenotypes. CN high tumors are stratified based on molecular level with two newly identified biomarkers. We pre-characterized a patient cohort compromising of 41 samples, using IHC (MLH1, MSH2, MSH6, PMS2 and the surrogate marker TP53). Using our proprietary molecular analysis platform MODAPLEX, that unifies PCR and capillary gel electrophoresis, we analyzed this cohort with the three assays with a 4-hour turn-around time. The concordance was determined by calculation of the sensitivity.
Results
The concordance analysis of our MODAPLEX assays revealed a sensitivity of 0.923 (95% CI [0.781, 1.066]) for MSI compared to the IHC results and 0.833 (95% CI [0.622, 1.044]) for CN high compared to p53-IHC, respectively. We verified 100% of the mutations identified with the MODAPLEX POLE/POLD1 assay.
Conclusions
Overall, this study demonstrates a multi-gene/multi-marker testing workflow with complete molecular stratification for EC into a single streamlined, time- and cost-effective run. This approach will allow timely access to molecular-guided therapy for individual patients by enabling same day results, with a relative ease of implementation and fully integrated data analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Biotype GmbH, Dresden, Germany.
Funding
Biotype GmbH, Dresden, Germany.
Disclosure
S. Walz, C. Schanzenbach, A. Aich, R. Weißbach, R. Braun, A. Hennig, J. Schoebel, S. Hofmann: Financial Interests, Institutional, Full or part-time Employment: Biotype GmbH.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract